Ex vivo drug sensitivity testing as a means for drug repurposing in esophageal adenocarcinoma.

Ines LohseHassan Al-AliClaude-Henry VolmarAnnamil D Alvarez TrottaShaun P BrothersAnthony J CapobiancoClaes Wahlestedt

Published in: PloS one (2018)

Ex vivo drug sensitivity testing may present a viable option for the treatment stratification of esophageal cancer patients and holds the potential to greatly improve patient outcome while reducing treatment toxicity.

Keyphrases

newly diagnosed
squamous cell carcinoma
emergency department
case report
prognostic factors
adverse drug
drug induced
combination therapy
risk assessment
radiation therapy
locally advanced
patient reported outcomes
human health
replacement therapy
patient reported